Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effects of Dronabinol in Opioid-Related Outcomes
NCT04025359Phase 1Recruiting
- Sponsor
- Yale University
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dronabinol in opioid use disorder (OUD) and pain (3 arms), sponsored by Yale University. Primary endpoints: Pain sensitivity measured by the Cold Pressor Test at 6 hours and Pain sensitivity measured by the Short form of the McGill Pain Questionnaire at 6 hours. Started May 2019; status: recruiting.
02
Drugs
dronabinol
03
Conditions
opioid use disorder (OUD)pain
Beyond the preview
Go deeper on NCT04025359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025359.